Supplementary Figure 15 from Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Year: 2023
Type: supplementary-materials
Abstract: MRD testing results in early stage breast cancer cohort. (A) Detection limits versus the number of SNVs tracked for each cfDNA sample. (B) Comparison of fingerprint size distributions between patients that were MRD+ at any time point and those that were always MRD-, split by distant recurrence status. The Mann-Whitney U test was used to determine whether MRD+ patients tracked significantly more mutations than MRD- patients. (C) Tumor fractions for MRD+ samples from patients with distant recurrence split by the minimum fingerprint size required to still detect MRD.
Authors: Heather A. Parsons, Justin Rhoades, Sarah C. Reed, Gregory Gydush, Priyanka Ram, Pedro Exman, Kan Xiong, Christopher C. Lo, Tianyu Li, Mark Fleharty, Gregory J. Kirkner, Denisse Rotem, Ofir Cohen, Fangyan Yu, Mariana Fitarelli-Kiehl, Ka Wai Leong, Melissa E. Hughes, Shoshana M. Rosenberg, Laura C. Collins, Kathy D. Miller, Brendan Blumenstiel, Lorenzo Trippa, Carrie Cibulskis, Donna S. Neuberg, Matthew DeFelice, Samuel S. Freeman, Niall J. Lennon, Nikhil Wagle, Gavin Ha, Daniel G. Stover, Atish D. Choudhury, Gad Getz, Eric P. Winer, Matthew Meyerson, Nancy U. Lin, Ian Krop, J. Christopher Love, G. Mike Makrigiorgos, Ann H. Partridge, Erica L. Mayer, Todd R. Golub, Viktor A. Adalsteinsson
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362411277